Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

sub-chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions

Data source

Reference Type:

Materials and methods

Test guideline
equivalent or similar to guideline
OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
GLP compliance:
Limit test:

Test material

Constituent 1
Chemical structure
Reference substance name:
Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acetate
EC Number:
EC Name:
Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acetate
Cas Number:
Molecular formula:
(1S,2S,4S) 1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acetate

Test animals

other: CFE
Details on test animals or test system and environmental conditions:
- Source:
- Weight at study initiation: 100-120 g (male) and 90-105 g (female)
- Housing: 5 per cage
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum

- Temperature (°C): 21 ± 1ºC
- Humidity (%): 50-60%

Administration / exposure

Route of administration:
oral: gavage
corn oil
Details on oral exposure:
- Amount of vehicle (if gavage): 5 ml total dose/kg/day
Analytical verification of doses or concentrations:
Duration of treatment / exposure:
13 weeks ( 0, 15, 90 or 270 mg/kg bw/day)
2 to 6 weeks (0, 90 or 270 mg/kg bw/day)
Frequency of treatment:
Doses / concentrationsopen allclose all
Dose / conc.:
0 mg/kg bw/day (actual dose received)
Dose / conc.:
15 mg/kg bw/day (actual dose received)
Dose / conc.:
90 mg/kg bw/day (actual dose received)
Dose / conc.:
270 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
15 male and 15 female: 0, 15, 90 or 270 mg/kg bw/day (13 weeks)
5 male and 5 female: 0, 90 or 270 mg/kg bw/day (2-6 weeks)
Control animals:


Observations and examinations performed and frequency:
- Time schedule for examinations: Weekly

- Time schedule for examinations: Weekly

- Time schedule for examinations: Weekly

- Time schedule for collection of blood: After receiving their final dose
- Anaesthetic used for blood collection: Yes (overdose of barbiturate)
- Animals fasted: Yes
- How many animals: All animals
- Parameters checked: The blood was examined for haemoglobin content, packed cell volume, counts of erythrocytes, reticulocytes and total and individual types of leucocyte. The serum was analysed for urea, glucose, total protein and albumin and the activities of glutamic-oxalacetic and glutamic-pyruvic transaminase and lactic dehydrogenase enzymes.

- Time schedule for collection of urine: final week of treatment
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters checked: appearance, microscopic constituents and content of glucose, ketones, bile salts and blood. A concentration and dilution test was carried out on the same rats.
- Others: At wk 2 this was limited to measurement of the volume and specific gravity of urine produced during a 6-hr period of water deprivation. At wk 6 and 13 similar measurements were made on the urine produced in 2 hr after a water load of 25 ml/kg and in a 4-hr period after 16 hr without water.
Sacrifice and pathology:
Gross abnormalities.
Organ weights: brain, pituitary, thyroid, heart, liver, spleen, adrenals, kidneys and gonads. In addition, after 13 wk of treatment the stomach, small intestine and caecum were weighed.

Samples of the above organs and of lung, lymph nodes, thymus, urinary bladder, colon, rectum, pancreas, uterus and muscle were preserved in 10% buffered formalin. Paraffin wax sections of these tissues were stained with haematoxylin and eosin for microscopic examination.

Results and discussion

Results of examinations

Clinical signs:
no effects observed
Description (incidence and severity):
No abnormalities in behaviour or appearance occurred during the study.
no mortality observed
Description (incidence):
No deaths occurred during the study.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
There were no significant differences between test and control animals in the rate of bodyweight gain during the treatment period, but a slight decrease in weight seen in males of the highest dosage group became significant after the 24-hr fast prior to death in animals killed at both 6 and 13 wk.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
No significant differences between test and control animals.
Food efficiency:
no effects observed
Description (incidence and severity):
No significant differences between test and control animals.
Water consumption and compound intake (if drinking water study):
effects observed, treatment-related
Description (incidence and severity):
Only in males treated with the higher dose increase of mean water consumption was observed.
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Description (incidence and severity):
After treatment for 6 or 13 wk there were no differences between the test and control groups in the results of the haematological studies.
Increases seen at wk 2 in the haemoglobin concentration in female rats and in total leucocyte counts in male rats receiving 270 mg IBA/kg and in erythrocyte counts in males given 90 or 270 mg/kg were not seen at wk 6 or 13. The reticulocyte count of all younger rats was higher than that of the older animals and red cells showed a marked polychromasia.
The results of the serum analyses were similar in test and control rats.
Clinical biochemistry findings:
not examined
Urinalysis findings:
effects observed, treatment-related
Description (incidence and severity):
The urine of all rats was of normal colour and free from glucose, blood, bile and ketones. The females treated with IBA gave results similar to those of female controls throughout.
In males there were no differences between control and IBA-treated rats at wk 2 but at wk 6 cell excretion was increased in rats receiving 270 mg/kg/day and at wk 13 this effect was seen also in animals receiving 90 mg/kg/day. The males given 270 mg/kg/day also showed an impairment of urine-concentrating ability.
At wk 6 this was seen only after prolonged (16-20 hr) water deprivation but at wk 13 it was also seen after dehydration for 6 hr.
At the lower dosage levels there were no significant changes in the results of the concentration test.
Behaviour (functional findings):
not specified
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
Although the absolute kidney weight was increased only in females at wk 13 the kidney weight expressed relative to body weight was increased at wk 6 in males and at wk 13 in both sexes.
The relative liver weight was increased in both sexes of rats given 270 mg/kg/day for 13 wk. There were no changes in liver weight at wk 2 or 6.
Both absolute and relative caecal weights were increased at wk 13 at the highest level of treatment.
Gross pathological findings:
no effects observed
Description (incidence and severity):
No abnormalities were seen at autopsy.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
Histological examination showed that there was a varying degree of pulmonary change suggestive of a mild infection; this was common to test and control animals.
Histological changes associated with IBA treatment were confined to treatment at the 270 mg/kg level. In the kidneys there was an increased incidence of focal tubular degeneration and atrophy and, in males only, a vacuolation of the tubular epithelium. Vacuolation of the epithelial cells of the intrahepatic bile ducts was also seen in males.
Histopathological findings: neoplastic:
not examined
Other effects:
no effects observed

Effect levels

Key result
Dose descriptor:
Effect level:
15 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:

Target system / organ toxicity

Key result
Critical effects observed:

Applicant's summary and conclusion

The NOEL of isobornyl acetate after an oral exposure of 13 weeks was 15 mg/kg bw/day in rats.
Executive summary:

A repeated dose toxicity study (oral route) was performed on isobornyl acetate according to a similar method to OECD guideline 408. The substance was dissolved in corn oil and administered daily to rats by stomach tube in doses: 0 (control), 15, 90 or 270 mg/kg body weight/day during 13 weeks. There were no differences between treated and control animals in the rate of body-weight gain, the food intake or the results of haematological investigations. In male rats given 270 mg/kg bw/day there was a decrease in renal concentrating ability, an increase in water intake, exfoliation of renal tubular cells, increased kidney weight and vacuolation of the renal tubular cells. Signs of nephrotoxicity were also seen with daily doses of 90 mg/kg bw/day. Vacuolation of the epithelium of the intrahepatic bile-duct and increase in liver weights were found at 270 mg/kg bw/day. The caecum were also enlarged at this dosage level. The no-effect level (NOEL) was found to be 15 mg/kg bw/day.